4-[(2-{4-[(5-butylthien-2-yl)carbonyl]piperidin-1-yl}-1,3-benzothiazol-6-yl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide hydrochloride | 701270-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-[(2-{4-[(5-butylthien-2-yl)carbonyl]piperidin-1-yl}-1,3-benzothiazol-6-yl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide hydrochloride
• 英文别名: 4-[(2-{4-[(5-butylthien-2-yl)carbonyl]piperidin-1-yl}-1,3-benzothiazol-6-yl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide Hydrochloride；4-[[2-[4-(5-butylthiophene-2-carbonyl)piperidin-1-yl]-1,3-benzothiazol-6-yl]sulfonyl]-N-hydroxyoxane-4-carboxamide;hydrochloride
• CAS: 701270-88-4
• 化学式: C₂₇H₃₃N₃O₆S₃*ClH
• 分子量: 628.234
• InChiKey: GIIHQVQOYOUAEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.05
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  191
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  4-[(2-{4-[(5-butylthien-2-yl)carbonyl]piperidin-1-yl}-1,3-benzothiazol-6-yl)sulfonyl]-N-(tetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-4-carboxamide 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 1.0h， 以81%的产率得到4-[(2-{4-[(5-butylthien-2-yl)carbonyl]piperidin-1-yl}-1,3-benzothiazol-6-yl)sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide hydrochloride
  参考文献：
  名称：

  [EN] HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS
  [FR] ACIDES ET AMIDES HETEROARYLSULFONYLMETHYL HYDROXAMIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PROTEASES

  摘要：

  公开号：

  WO2004048368A3

文献信息

• Aryl carbonyl derivatives as therapeutic agents
  申请人：——

  公开号：US20040122235A1

  公开（公告）日：2004-06-24

  This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

  本发明涉及芳基羰基衍生物，其是葡萄糖激酶的激活剂，可用于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病。
• Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
  申请人：——

  公开号：US20040142979A1

  公开（公告）日：2004-07-22

  This invention is directed generally to heteroarylsulfonylmethyl hydroxamic acids and amides that, inter alia, tend to inhibit protease activity, particularly matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to compositions of such compounds; intermediates for the syntheses of such compounds; methods for making such compounds; and methods for treating conditions associated with MMP, tumor necrosis factors (or “TNFs”), and/or aggrecanase activity, particularly pathological conditions.

  本发明一般涉及杂环烷基磺酰甲基羟肟酸和酰胺，该类化合物具有抑制蛋白酶活性（特别是基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或Aggrecanase活性）的倾向。本发明还涉及这些化合物的组合物；合成这些化合物的中间体；制备这些化合物的方法；以及治疗与MMP、肿瘤坏死因子（或“TNFs”）和/或Aggrecanase活性相关的病理情况的方法。
• A NEW ORAL IMMEDIATED RELEASE DOSAGE FORM
  申请人：AstraZeneca AB

  公开号：EP1572158A1

  公开（公告）日：2005-09-14
• HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS
  申请人：Pharmacia Corporation

  公开号：EP1565459A2

  公开（公告）日：2005-08-24
• [EN] A NEW ORAL IMMEDIATED RELEASE DOSAGE FORM<br/>[FR] NOUVELLE FORME DE DOSAGE ORALE A LIBERATION IMMEDIATE
  申请人：ASTRAZENECA AB

  公开号：WO2004052342A1

  公开（公告）日：2004-06-24

  The present invention relates to a solid oral immediate release dosage form of a pharmaceutically active compound, N-[(1,2,3,4-tetrahydro-5-methyl-8-(4-methylpiperazin-1-yl)-2-naphthyl]-4-morpholinobenzamide, in the form of the free base or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing said dosage form, the use of said dosage form and a method of prevention and/or treatment of CNS disorders and related medical disturbances using said dosage form.